Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR-T cells in pediatric R/R ALL/LBL
NCT05333302Phase 1Recruiting
- Sponsor
- Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
- Start
- Oct 2020
- Primary completion
- Dec 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CD19 CAR-T-cells in B cell acute lymphoblastic leukemia (B-ALL) and B-cell lymphoblastic lymphoma (B-LBL), sponsored by Belarusian Research Center for Pediatric Oncology, Hematology and Immunology. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 1 month. Started Oct 2020; status: recruiting.
02
Drugs
CD19 CAR-T-cells
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B-cell lymphoblastic lymphoma (B-LBL)
Beyond the preview
Go deeper on NCT05333302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05333302.